CA Patent

CA2215716C — Aerosol delivery of liposome-encapsulated fluoroquinolone

Assigned to Minister of National Defence of Canada · Expires 1999-12-07 · 26y expired

What this patent protects

The therapeutic efficacy of liposome-encapsulated fluoroquinolone for the treatment respiratory infections is enhanced by providing a delivery system capable of targeting the drug directly to the infection site using aerosol delivery.

USPTO Abstract

The therapeutic efficacy of liposome-encapsulated fluoroquinolone for the treatment respiratory infections is enhanced by providing a delivery system capable of targeting the drug directly to the infection site using aerosol delivery.

Drugs covered by this patent

amikacin-sulfate (AMIKACIN SULFATE)

Patent Metadata

Patent number: CA2215716C
Jurisdiction: CA
Classification: —
Expires: 1999-12-07
Drug substance claim: No
Drug product claim: No
Assignee: Minister of National Defence of Canada
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.